<DOC>
	<DOCNO>NCT00504634</DOCNO>
	<brief_summary>Primary Objective : 1 . To determine antimyeloma effect bortezomib allogeneic transplantation patient multiple myeloma . Secondary Objective 1 . To determine toxicity profile bortezomib patient multiple myeloma undergo allogeneic progenitor cell transplantation .</brief_summary>
	<brief_title>Bortezomib ( Velcade ) Post Allogenic Peripheral Blood Stem Cell Transplantation Myeloma</brief_title>
	<detailed_description>Bortezomib ( velcade ) new drug work block structure cell call proteasome . This proteasome act like system eliminate abnormal old protein cell . Cancer cell may sensitive drug like bortezomib ( velcade ) , tumor cell abnormal protein normal cell . Bortezomib ( velcade ) enter tumor cell affect way divide . When cancer cell divide , die . You blood ( 2 tablespoon ) bone marrow test do every 2-3 month determine response tolerance treatment . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . You receive bortezomib ( velcade ) infusion vein 5-10 minute twice week 2 week . You rest 10 17 day . This 21-28 day period make 1 cycle . You complete total 4 cycle . Courses 2 3 might give supervision local physician however principal investigator necessary treatment dose adjustment new set treatment order provide physician . Treatment evaluation supervision principal investigator . You physical exam routine blood test ( 2 tablespoon ) dose bortezomib ( velcade ) . Blood ( 2 tablespoon ) urine test determine response treatment perform month , well blood test look side effect treatment , perform least week frequently medically necessary . You take study disease get bad intolerable side effect occur . You call every 3 month least 1 year last dose bortezomib ( velcade ) see . This investigational study . Bortezomib ( velcade ) commercially available indicated treatment myeloma . A total 28 patient participate study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients multiple myeloma least 3 month post allogeneic transplant either fail achieve complete remission relapse . Allograft perform related donor HLAcompatible ( 5/6 6/6 ) , class I serologic match class II molecular match unrelated donor ) . Zubrod Points Scale ( PS ) &lt; 2 , life expectancy severely limited concomitant illness . Patient willing able sign inform consent . Patients le 70 year age . Active Central Nervous System ( CNS ) disease . Uncontrolled acute chronic Graftversushost disease ( GVHD ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Post Allogeneic Transplantation</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>PS-341</keyword>
</DOC>